Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

Therapeutic combinations targeting innate and adaptive immunity and predictive biomarkers of response in esophagogastric cancer (EGC) are needed. We assessed safety and clinical utility of DKN-01 (a novel DKK1-neutralizing IgG4 antibody) combined with pembrolizumab and retrospectively determined DKK...

Descripción completa

Detalles Bibliográficos
Autores principales: Klempner, Samuel J., Bendell, Johanna C., Villaflor, Victoria Meucci, Tenner, Laura LaNiel, Stein, Stacey M., Rottman, James B., Naik, Girish S., Sirard, Cynthia A., Kagey, Michael H., Chaney, Marya F., Strickler, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398109/
https://www.ncbi.nlm.nih.gov/pubmed/34482288
http://dx.doi.org/10.1158/1535-7163.MCT-21-0273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398109/
https://www.ncbi.nlm.nih.gov/pubmed/34482288
http://dx.doi.org/10.1158/1535-7163.MCT-21-0273

Ejemplares similares